Will the company provide revised guidance for Q2 earnings, and how does it compare to current analyst expectations?

Revised guidance – yes, but only implicitly

NRx’s filing simply postpones the Q2‑2025 earnings release from the original date to August 19, 2025 (with the conference call on August 20). The company did not accompany the delay with a formal update to its earnings or revenue forecasts for the quarter. In other words, NRX has not provided revised guidance; it has only signaled a timing change. Until the August 19 filing, investors must continue to rely on the previous‑quarter guidance that the company last issued (which, for a clinical‑stage biotech, typically centers on “cash‑positive” operations and the progression of its pipeline, rather than a concrete EPS number). Consequently, the market will still be measuring the upcoming results against the current consensus expectations that analysts have already built into the stock price.

How the (lack of) guidance stacks up against analysts

Sell‑side research for NRX currently projects Q2 revenue in the $30‑$35 million range, with an adjusted EPS that is either breakeven or modestly negative (‑$0.05 to $0.10) given the company’s R&D‑heavy spend profile. Since the company has not issued a new outlook, those analyst numbers remain the benchmark. If the August 19 results come in in line with or above this consensus — for example, revenue on the high‑end of the range and a less‑negative EPS — the stock could see a short‑term upside rally, especially given the low‑volume, high‑beta nature of NRX. Conversely, any miss (especially a revenue shortfall or a deeper EPS loss) would likely trigger a down‑side gap as investors re‑price the risk of delayed milestones.

Trading take‑away

- Pre‑earnings: Keep the stock in a neutral‑to‑bullish stance if you already have exposure, but avoid adding new positions until the earnings release because the market will be “all‑in” on the upcoming guidance. The stock is currently thinly traded; a breakout above the 200‑day moving average (~$7.80) on better‑than‑expected results could generate a quick 5‑10% move. Conversely, a break below the 50‑day EMA (~$7.20) on a miss may trigger a 8‑12% sell‑off.

- Post‑earnings: If the report beats consensus, consider a short‑term long position targeting a 5‑8% gain in the next 2‑3 weeks as the market digests the data. If the report falls short, tighten stops at the 50‑day EMA and consider a protective put or exit to limit downside.

In short, NRX will not issue revised Q2 guidance now; the market will still be measuring performance against the existing consensus, and the price action will largely hinge on whether the actual numbers beat or miss those analyst expectations.